| ROCHE HLDG AG GEN. | 239.50 / +1.08% |
| Date/Time | 03/22 / 14:49 |
| Chg. / Chg.(%) | 2.55 / +1.08% |
| Bid | 239.20 / 200 |
| Ask | 239.45 / 262 |
| Open | 239.95 |
| Previous Close | 236.95 |
| High | 241.30 |
| Low | 239.50 |
| Volume [EUR] | 863,564.85 |
| Volume [Units] | 3,590 |
| Price fixings | 59 |
| ISIN | CH0012032048 |
| Security | RHO5 |
| Exchange | Xetra |
| Type | Stock |
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 268.95 |  |
570,259 |
| Cboe Europe .. | 268.95 | |
76,480 |
| Turquoise | 268.95 | |
74,775 |
| London Inter.. | 269.35 | |
18,692 |
| Xetra | 239.50 |  |
3,590 |
| TradeGate | 239.650 | |
1,218 |
| Frankfurt | 240.200 | |
964 |
| München | 240.35 | |
280 |
| Berlin | 239.80 | |
70 |
| Stuttgart | 239.800 | |
50 |
| Borsa Italia.. | 241.30 | |
20 |
| Düsseldorf | 239.80 | |
0 |
| Hamburg | 239.20 | |
0 |
| Lang & Schwa.. | 239.350 | |
|
| gettex | 239.750 | |
|
| Mexico | 5,133.38 |  |
24,780 |
| Nasdaq Other.. | 271.0000 | 489 | |
| Mexico | 4,744.44 | 32 | |
| Borsa Italia.. | 238.00 | ||
| EUREX | Options | ||
News
- Biopharmaceuticals Market Analysis & Outlook, 2019 to 2024 - Their Ability to Treat Previously Untreatable Diseases is Spurring Growth
03/20/2019 / 12:40 - GlobeNewswire - FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
03/19/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease
03/15/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
03/14/2019 / 07:00 - GlobeNewswire - Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
03/11/2019 / 07:03 - GlobeNewswire
Real-time